Enanta Pharmaceuticals (ENTA)
ENTA · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Infectious Diseasesrc
Signal Snapshot
2
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
1 Phase 1, 1 Phase 2
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial. — Nat Med (2026) PMID 42557458
- The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial. — Lancet Gastroenterol Hepatol (2026) PMID 42480572
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Enanta Pharmaceuticals.
Full ENTA Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.